Biolex Reports Progress in Hepatitis C Treatment
Posted April 28, 2006
PITTSBORO, N.C. — Biolex Therapeutics
reported positive results in a Phase I trial of a proposed drug to treat Hepatitis C.
Biolex is developing the drug Locteron along with OctoPlus, a firm based in the Netherlands.
The drug is centered around a compound, BLX-883, developed by Biolex and a controlled-release drug delivery system designed by OctoPlus.
The two companies plan to launch Phase II clinical testing in the second half of this year.